The Committee for Medicinal Products for Human Use positive opinion and the European Commission, which approves pharmaceuticals follows, usually CHMP recommendations. Hospira anticipates European Union approval for Retacrit in late 2007 Geneerinen Priligy . The company plans product product – which will be Hospira’s first marketed similar biologic – in various EU countries from early 2008. As the world leader in generic injectables, Hospira is ready to bring high-quality, lower-cost similar biologics in patients We are pleased under these agreements, this milestone for this important medication, ‘says Michael Kotsanis, president, Europe, Middle East and Africa, Hospira. ‘Similar biologics like Retacrit can help provide safe, effective patient care, reducing while contributing to global healthcare costs ‘. – end of 2006, Hospira, STADA and BIOCEUTICALS Arzneimittel AG, a project initiated by STADA announced, development, manufacturing and distribution agreements for epoetin zeta. Under these agreements, Hospira receives the exclusive distribution rights for the product in countries like the U.S. And most of Europe; with the exception of Germany, where Hospira and STADA will both market the product the epoetin zeta project is pursued through BIOCEUTICALS STADA controlled the development process and led to the approval process on behalf of BIOCEUTICALS and Hospira.
In the recently completed measles study in infant nonhuman primates, exceeded neutralizing antibody levels of acceptable threshold before the second injection at Week 4, reached at week 8 and remained above the threshold at least through the 20-week follow-up period. The animals were intratracheal intratracheal inoculation after one year what. Complete protection of all vaccinated animals In addition animals had disease symptoms or culturable levels of measles virus, in contrast to animals, the negative control, all had rashes and positive virus cultures. No adverse events associated with vaccination was observed. Read More